Masashi Nomura, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioma | 5 | 2021 | 3401 | 0.640 |
Why?
|
| Cerebellar Neoplasms | 1 | 2017 | 587 | 0.420 |
Why?
|
| Spondylitis | 1 | 2011 | 22 | 0.390 |
Why?
|
| Actinomycosis | 1 | 2011 | 21 | 0.390 |
Why?
|
| Brain Neoplasms | 7 | 2021 | 8860 | 0.390 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2011 | 139 | 0.360 |
Why?
|
| Oligodendroglioma | 3 | 2021 | 279 | 0.340 |
Why?
|
| Isocitrate Dehydrogenase | 3 | 2019 | 871 | 0.330 |
Why?
|
| Astrocytoma | 3 | 2021 | 789 | 0.290 |
Why?
|
| Osteomyelitis | 1 | 2011 | 402 | 0.290 |
Why?
|
| Cervical Vertebrae | 1 | 2011 | 975 | 0.240 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2024 | 281 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 19 | 2 | 2021 | 367 | 0.190 |
Why?
|
| Rhodamines | 1 | 2021 | 183 | 0.190 |
Why?
|
| Ependymoma | 1 | 2024 | 334 | 0.190 |
Why?
|
| Enchondromatosis | 1 | 2018 | 14 | 0.170 |
Why?
|
| Sella Turcica | 1 | 2018 | 119 | 0.160 |
Why?
|
| Epigenesis, Genetic | 4 | 2024 | 3646 | 0.160 |
Why?
|
| Cefazolin | 1 | 2018 | 96 | 0.160 |
Why?
|
| Phenylthiohydantoin | 1 | 2019 | 192 | 0.160 |
Why?
|
| Hemangioblastoma | 1 | 2017 | 70 | 0.150 |
Why?
|
| Brain Stem Neoplasms | 1 | 2018 | 204 | 0.140 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2017 | 152 | 0.140 |
Why?
|
| Immune Evasion | 1 | 2019 | 360 | 0.130 |
Why?
|
| Skull Base Neoplasms | 1 | 2018 | 284 | 0.130 |
Why?
|
| CpG Islands | 1 | 2019 | 1172 | 0.120 |
Why?
|
| Hematoma, Subdural, Chronic | 1 | 2015 | 90 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1039 | 0.110 |
Why?
|
| Fluorescent Dyes | 1 | 2021 | 1917 | 0.110 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2018 | 638 | 0.110 |
Why?
|
| Mutation | 8 | 2024 | 29784 | 0.110 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2018 | 895 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 6535 | 0.100 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 1987 | 0.100 |
Why?
|
| Cell Nucleus | 1 | 2020 | 2969 | 0.100 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2019 | 1581 | 0.100 |
Why?
|
| Cerebellum | 1 | 2017 | 1490 | 0.090 |
Why?
|
| Bacterial Infections | 1 | 2018 | 1401 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2019 | 9230 | 0.090 |
Why?
|
| RNA-Binding Proteins | 1 | 2019 | 1903 | 0.090 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 2183 | 0.090 |
Why?
|
| Diplopia | 1 | 2011 | 200 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2019 | 4217 | 0.090 |
Why?
|
| Tooth Extraction | 1 | 2011 | 222 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2018 | 1509 | 0.090 |
Why?
|
| Prostate-Specific Antigen | 1 | 2019 | 2478 | 0.090 |
Why?
|
| Androgen Antagonists | 1 | 2018 | 1361 | 0.080 |
Why?
|
| Glioblastoma | 2 | 2021 | 3481 | 0.080 |
Why?
|
| Postoperative Complications | 3 | 2018 | 15294 | 0.080 |
Why?
|
| Penicillins | 1 | 2011 | 380 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2020 | 8426 | 0.080 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2019 | 2737 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2021 | 658 | 0.080 |
Why?
|
| Cell Cycle Proteins | 1 | 2019 | 3461 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 5867 | 0.070 |
Why?
|
| Periodontal Diseases | 1 | 2011 | 449 | 0.070 |
Why?
|
| Bone and Bones | 1 | 2018 | 2575 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 2 | 2018 | 7179 | 0.070 |
Why?
|
| Infusions, Intravenous | 1 | 2011 | 2272 | 0.070 |
Why?
|
| Disease Progression | 2 | 2019 | 13280 | 0.070 |
Why?
|
| Bone Density | 1 | 2018 | 3468 | 0.060 |
Why?
|
| Adult | 12 | 2024 | 214035 | 0.060 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 57768 | 0.060 |
Why?
|
| Genomics | 1 | 2020 | 5722 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2011 | 3913 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2021 | 6313 | 0.050 |
Why?
|
| Aged | 10 | 2019 | 163253 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2011 | 2017 | 0.050 |
Why?
|
| Gene Expression Profiling | 3 | 2024 | 9438 | 0.050 |
Why?
|
| Prognosis | 5 | 2021 | 29050 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 12961 | 0.050 |
Why?
|
| Middle Aged | 10 | 2019 | 213367 | 0.050 |
Why?
|
| Humans | 17 | 2024 | 744220 | 0.050 |
Why?
|
| Freezing | 1 | 2020 | 303 | 0.040 |
Why?
|
| Algorithms | 1 | 2020 | 13885 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2021 | 689 | 0.040 |
Why?
|
| Microarray Analysis | 1 | 2021 | 766 | 0.040 |
Why?
|
| Prostatic Neoplasms | 2 | 2018 | 11074 | 0.040 |
Why?
|
| Perineum | 1 | 2018 | 211 | 0.040 |
Why?
|
| Male | 11 | 2019 | 350027 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 13668 | 0.030 |
Why?
|
| Anisotropy | 1 | 2019 | 1265 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2015 | 35423 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 17449 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 6274 | 0.030 |
Why?
|
| Young Adult | 5 | 2019 | 56436 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 39045 | 0.030 |
Why?
|
| Nitriles | 1 | 2019 | 952 | 0.030 |
Why?
|
| Benzamides | 1 | 2019 | 1378 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2020 | 3689 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2018 | 1401 | 0.030 |
Why?
|
| Retrospective Studies | 5 | 2019 | 77426 | 0.030 |
Why?
|
| DNA Methylation | 2 | 2017 | 4289 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 2013 | 0.030 |
Why?
|
| Neoplasms | 1 | 2020 | 21672 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2018 | 1000 | 0.020 |
Why?
|
| Prostate | 1 | 2018 | 1773 | 0.020 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2019 | 2305 | 0.020 |
Why?
|
| Computational Biology | 1 | 2020 | 3523 | 0.020 |
Why?
|
| Child | 3 | 2024 | 77679 | 0.020 |
Why?
|
| Female | 7 | 2020 | 380197 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 4841 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 3598 | 0.020 |
Why?
|
| Biopsy | 1 | 2018 | 6757 | 0.020 |
Why?
|
| Risk Factors | 3 | 2018 | 72280 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 8628 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2020 | 14556 | 0.020 |
Why?
|
| Survival Rate | 1 | 2019 | 12781 | 0.020 |
Why?
|
| Mice | 2 | 2021 | 81178 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 11007 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 13990 | 0.010 |
Why?
|
| Recurrence | 1 | 2015 | 8343 | 0.010 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2015 | 3068 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 12244 | 0.010 |
Why?
|
| Logistic Models | 1 | 2015 | 13409 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2015 | 4599 | 0.010 |
Why?
|
| Adolescent | 2 | 2019 | 85759 | 0.010 |
Why?
|
| Animals | 2 | 2021 | 168788 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 15525 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2017 | 40559 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2019 | 63119 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 20123 | 0.010 |
Why?
|